New treatments for drug-resistant tuberculosis (TB) have brought hope to patients, but access to these medicines and their pricing have been simmering issues in some resource-constrained high-burden markets.
The TB Alliance has been moving at a fast clip sewing up alliances to ensure an affordable, sustainable and competitive market for its new TB drug, pretomanid, approved in combination with Johnson & Johnson’s Sirturo (bedaquiline) and Pfizer Inc.’s Zyvox (linezolid) by the US FDA in August, for treating adult patients with extensively drug-resistant, treatment-intolerant or non-responsive multi-drug resistant pulmonary TB (MDR-TB)